Short interest for Aeolus Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Aeolus Pharmaceuticals's stock. Short interest data is updated every two weeks.

Aeolus Pharmaceuticals Stock Short Interest Report | OTC:AOLS | Benzinga

AEOLUS PHARMS INC by Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals

Overview

News

Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.

Comments

Aeolus Pharmaceuticals Short Interest Report

Aeolus Pharmaceuticals Stock Short Interest Report | OTC:AOLS | Benzinga